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Re: Coffee Consumption 
and Prostate Cancer 
Risk and Progression in 
the Health Professional 
Follow-up Study
In a previous issue of the Journal, Wilson 
et al. (1) reported on data from the Health 
Professional Follow-up Study, which 
showed a negative association between cof-
fee consumption and risk of prostate can-
cer, particularly lethal prostate cancer as 
defined by the authors. The report dealt 
with possible bias (eg, reverse causation) 
very carefully, and it reached conclusions 
at variance with previous null or positive 
associations (2). Confounding by tobacco 
smoking and lack of distinction between 
subsets of prostate cancer were mentioned 
as possible causes for the null associations 
found in previous studies (1).
To shed further light on this topic, we 
used data from a large Italian hospital–
based case–control study (3) that assessed 
the relationship between coffee intake 
and risk of benign prostatic hyperpla-
sia (BPH) and prostate cancer. The daily 
intake of regular and decaffeinated coffee 
during the 2 years preceding enrollment, 
together with information on smoking and 
drinking habits and other relevant varia-
bles (4), was assessed through a validated 
food-frequency questionnaire (5). Gleason 
scores could be retrieved from patho-
logical records for 71% of patients with 
prostate cancer. Odds ratios were calcu-
lated by means of logistic regression mod-
els, adjusting for potential confounders.
We found no statistically significant 
associations between coffee consumption 
and the risk of BPH or prostate cancer 
(Table  1), and no differences were found 
when we stratified by tumor grade (ie, 
Gleason score 2–6, 7–10, or unknown). 
Tobacco smoking was not a likely con-
founder of our results, because no het-
erogeneous association between coffee 
intake and risk of BPH or prostate cancer 
emerged in strata of never, light, or heavy 
smokers.
The hypothesis that coffee may lower 
prostate cancer risk by reducing glucose 
response and improving insulin sensi-
tivity (1) is an interesting one, because 
prostate cancer was positively associated 
with insulin level (6). However, this result 
needs further investigation because the 
stronger effect of coffee consumption 
on high-grade prostate cancer found by 
Wilson et  al. (1) did not fully match the 
stronger association of insulin-like growth 
factor 1 with low-grade prostate can-
cer—rather than with high-grade pros-
tate cancer—in the Health Professional 
Follow-up Study (7).
Studies from North America have 
tended to report negative associations 
between prostate cancer and coffee intake 
more often than studies from Europe (2). 
Differences in coffee consumption, cof-
fee bean roasting, and brewing methods, 
as well as differences between prostate 
cancer–risk profiles among men in the 
United States vs those in Italy, could 
partly explain these differences (2). Our 
results suggested that smoking habits did 
not confound the association between 
coffee consumption and risk of prostate 
cancer. Nonetheless, other factors (eg, 
overweight), or variations in coffee con-
sumption across different ethnic subsets 
of the US population, may have affected 
the findings from the Health Professional 
Follow-up Study (1).
Selection and recall biases cannot be 
ruled out in our study; however, fewer than 
5% of eligible subjects refused to participate 
in our study and the questionnaire that we 
used had been successfully tested for repro-
ducibility and validity (5). In addition, we 
were unable to restrict our analysis to lethal 
prostate cancer cases, as presented in the 
analysis of Wilson et al. (1). Nonetheless, our 
results do not lend support to a protective 
effect of high coffee consumption on pros-
tate cancer or high-grade prostate cancer.
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Response
We are grateful for the opportunity to com-
ment on the letter by Polesel et al. on their 
study on coffee and prostate cancer risk. 
Indeed, given the novel findings of our ini-
tial report, we recognize the important role 
of the research community in validating 
these results in additional study populations.
The authors report no evidence for an 
inverse association between coffee con-
sumption and the risk of total prostate 
cancer or Gleason grade 7–10 disease. 
It is noteworthy that the odds ratios and 
confidence intervals reported in the cor-
respondence are, in fact, compatible with 
our own results. We found only a modest 
inverse association for total prostate cancer 
risk, and for grade 8–10 cancers, we found 
an inverse association only in the highest 
category of intake with no dose-response. 
Moreover, although rereviewed Gleason 
grade is an important predictor of pros-
tate cancer outcomes, there are inherent 
challenges in deriving grade information 
from original pathology reports. There 
are well-documented shifts in grading over 
time and across institutions (1,2), which may 
influence epidemiological studies that use 
historical Gleason data, including our own.
As the authors note, the substantially lower 
risk was found for lethal and advanced pros-
tate cancer among coffee drinkers. The data 
on stage and outcomes represent “harder” 
outcomes with less misclassification. Neither 
these results from the Italian hospital–based 
case–control study nor the meta-analysis by 
Park et  al. (3) cited in the correspondence 
studied lethal or advanced stage cancer sep-
arately. Because of the great heterogeneity 
in the biological potential of prostate can-
cers, and the use of prostate-specific antigen 
screening, we consider the study of advanced 
and lethal prostate cancer to be critical to our 
understanding of clinically relevant prostate 
cancer.
Although high grade confers the poten-
tial for prostate cancer to be aggressive, it is 
conceptually distinct from lethal cancer in 
that progression of a localized, high-grade 
tumor can theoretically be prevented. As 
such, high-grade disease is not a surro-
gate for lethal disease, and small, localized 
high-grade cancers may actually mark the 
presence of protective factors.
In response to their comments on con-
founding by smoking, we maintain that it 
will mainly be an issue for the study of lethal 
or advanced prostate cancer because smok-
ing is associated with more aggressive dis-
ease but not with overall incidence (4). Also, 
the degree of confounding by smoking will 
vary between populations by the prevalence 
of smoking and its link with coffee intake.
We agree that more studies on mech-
anism are needed. However, the argument 
of the correspondents about insulin-like 
growth factor 1 does not distinguish 
between insulin and insulin growth factor 
(IGF)-1. Insulin is associated with pros-
tate cancer progression (5), whereas total 
IGF-1 is not (6). In addition, insulin levels 
and insulin resistance are affected by coffee 
intake, but IGF-1 is not (7).
We hope others will examine the cof-
fee–prostate cancer association, particularly 
for lethal prostate cancer. We also wonder 
whether the authors might have the abil-
ity to link their study data with outcome 
data to study prostate cancer mortality or 
whether they may have sufficient numbers 
of Gleason 8–10 cancers to look at this 
highest risk group.
KATHRYN M. WILSON
EDWARD GIOVANNUCCI
LORELEI A. MUCCI
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